Polaryx Therapeutics, Inc. (PLYX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.81

From 52W high−94.89%

Volume8023.00

Market cap$89.22M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.81

From 52W high

−94.89%

Volume

8023.00

Market cap

$89.22M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.3x

P/E (TTM)

—

RSI (14)

43.6

MomentumView details →

1D Return

+3.47%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

8.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−62.61%

ROA (TTM)

−57.98%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−18.75%

EBITDA YoY

+9.33%

MomentumView details →

1D Return

+3.47%

YTD Return

—

1Y Return

—

RSI (14)

43.6

vs 50D SMA

−7.71%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.53x

Quick Ratio

13.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

14.29%

Beats (12Q)

1/12

Next Q EPS Est

−$0.05

Avg Surprise (4Q)

−45.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−6.85M

Op. CF (TTM)

−5.81M

Next earningsNov 12, 2026 →

Latest newsMore news →

Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.71d ago

Polaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.161d ago

Similar companies

Neonc Technologies Holdings, Inc.NTHI Lixte Biotechnology Holdings, Inc.LIXT Cibus, Inc.CBUS Tonix Pharmaceuticals Holding Corp.TNXP Vaxart, Inc.VXRT Genelux CorporationGNLX Find similar companies →

Latest newsMore news →

Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.71d ago Polaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.161d ago